Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scutellaria barbata chloroform extract (ECSB) is a research-grade compound derived from the traditional Chinese medicinal herb *Scutellaria barbata* D. Don. It is primarily investigated for its antitumor properties in preclinical models of colorectal, colon, and cervical cancers. The extract functions by inducing apoptosis and inhibiting cell proliferation through the modulation of multiple molecular targets, including the Bax/Bcl-2 ratio, cyclin D1, and cyclin-dependent kinase 4 (CDK4). Additionally, ECSB has been shown to regulate microRNA expression, specifically upregulating miR-34a and miR-195-5p, the latter of which targets LOXL2 to suppress malignant phenotypes. It also modulates key signaling pathways such as STAT3, ERK, and p38 MAPK. The active constituents of the extract include various flavonoids and diterpenoids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scutellaria barbata chloroform extract.